381 related articles for article (PubMed ID: 16492540)
21. Amylin receptors: molecular composition and pharmacology.
Hay DL; Christopoulos G; Christopoulos A; Sexton PM
Biochem Soc Trans; 2004 Nov; 32(Pt 5):865-7. PubMed ID: 15494035
[TBL] [Abstract][Full Text] [Related]
22. In vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain.
Paxinos G; Chai SY; Christopoulos G; Huang XF; Toga AW; Wang HQ; Sexton PM
J Chem Neuroanat; 2004 Jul; 27(4):217-36. PubMed ID: 15261329
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Hay DL; Christopoulos G; Christopoulos A; Poyner DR; Sexton PM
Mol Pharmacol; 2005 May; 67(5):1655-65. PubMed ID: 15692146
[TBL] [Abstract][Full Text] [Related]
24. Refolding and characterization of a soluble ectodomain complex of the calcitonin gene-related peptide receptor.
Koth CM; Abdul-Manan N; Lepre CA; Connolly PJ; Yoo S; Mohanty AK; Lippke JA; Zwahlen J; Coll JT; Doran JD; Garcia-Guzman M; Moore JM
Biochemistry; 2010 Mar; 49(9):1862-72. PubMed ID: 20099900
[TBL] [Abstract][Full Text] [Related]
25. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution.
Lennerz JK; Rühle V; Ceppa EP; Neuhuber WL; Bunnett NW; Grady EF; Messlinger K
J Comp Neurol; 2008 Mar; 507(3):1277-99. PubMed ID: 18186028
[TBL] [Abstract][Full Text] [Related]
26. Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat.
Oliver KR; Kane SA; Salvatore CA; Mallee JJ; Kinsey AM; Koblan KS; Keyvan-Fouladi N; Heavens RP; Wainwright A; Jacobson M; Dickerson IM; Hill RG
Eur J Neurosci; 2001 Aug; 14(4):618-28. PubMed ID: 11556887
[TBL] [Abstract][Full Text] [Related]
27. Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs.
Sexton PM; Morfis M; Tilakaratne N; Hay DL; Udawela M; Christopoulos G; Christopoulos A
Ann N Y Acad Sci; 2006 Jul; 1070():90-104. PubMed ID: 16888151
[TBL] [Abstract][Full Text] [Related]
28. Enhanced vascular responses to adrenomedullin in mice overexpressing receptor-activity-modifying protein 2.
Tam CW; Husmann K; Clark NC; Clark JE; Lazar Z; Ittner LM; Götz J; Douglas G; Grant AD; Sugden D; Poston L; Poston R; McFadzean I; Marber MS; Fischer JA; Born W; Brain SD
Circ Res; 2006 Feb; 98(2):262-70. PubMed ID: 16373602
[TBL] [Abstract][Full Text] [Related]
29. International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor.
Hay DL; Poyner DR; Quirion R;
Pharmacol Rev; 2008 Jun; 60(2):143-5. PubMed ID: 18552275
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor.
Armour SL; Foord S; Kenakin T; Chen WJ
J Pharmacol Toxicol Methods; 1999 Dec; 42(4):217-24. PubMed ID: 11033437
[TBL] [Abstract][Full Text] [Related]
31. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
Houssami S; Findlay DM; Brady CL; Martin TJ; Epand RM; Moore EE; Murayama E; Tamura T; Orlowski RC; Sexton PM
Mol Pharmacol; 1995 Apr; 47(4):798-809. PubMed ID: 7723741
[TBL] [Abstract][Full Text] [Related]
32. Adrenomedullin receptors: pharmacological features and possible pathophysiological roles.
Kuwasako K; Cao YN; Nagoshi Y; Kitamura K; Eto T
Peptides; 2004 Nov; 25(11):2003-12. PubMed ID: 15501534
[TBL] [Abstract][Full Text] [Related]
33. Novel calcitonin-(8-32)-sensitive adrenomedullin receptors derived from co-expression of calcitonin receptor with receptor activity-modifying proteins.
Kuwasako K; Kitamura K; Nagoshi Y; Eto T
Biochem Biophys Res Commun; 2003 Feb; 301(2):460-4. PubMed ID: 12565884
[TBL] [Abstract][Full Text] [Related]
34. Ligand binding and activation of the CGRP receptor.
Conner AC; Simms J; Barwell J; Wheatley M; Poyner DR
Biochem Soc Trans; 2007 Aug; 35(Pt 4):729-32. PubMed ID: 17635135
[TBL] [Abstract][Full Text] [Related]
35. Role of the N-terminal domain of the calcitonin receptor-like receptor in ligand binding.
Chauhan M; Rajarathnam K; Yallampalli C
Biochemistry; 2005 Jan; 44(2):782-9. PubMed ID: 15641806
[TBL] [Abstract][Full Text] [Related]
36. Calcitonin and Amylin Receptor Peptide Interaction Mechanisms: INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS.
Lee SM; Hay DL; Pioszak AA
J Biol Chem; 2016 Apr; 291(16):8686-700. PubMed ID: 26895962
[TBL] [Abstract][Full Text] [Related]
37. Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition.
Leuthäuser K; Gujer R; Aldecoa A; McKinney RA; Muff R; Fischer JA; Born W
Biochem J; 2000 Oct; 351 Pt 2(Pt 2):347-51. PubMed ID: 11023820
[TBL] [Abstract][Full Text] [Related]
38. Differential antagonism of amylin's metabolic and vascular actions with amylin receptor antagonists.
Beaumont K; Moore CX; Pittner RA; Prickett KS; Gaeta LS; Rink TJ; Young AA
Can J Physiol Pharmacol; 1995 Jul; 73(7):1025-9. PubMed ID: 8846395
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterization of novel alpha-Calcitonin Gene-Related Peptide (CGRP) receptor peptide antagonists that are selective for human CGRP receptors.
Taylor CK; Smith DD; Hulce M; Abel PW
J Pharmacol Exp Ther; 2006 Nov; 319(2):749-57. PubMed ID: 16873605
[TBL] [Abstract][Full Text] [Related]
40. A key role for tryptophan 84 in receptor activity-modifying protein 1 in the amylin 1 receptor.
Gingell JJ; Qi T; Bailey RJ; Hay DL
Peptides; 2010 Jul; 31(7):1400-4. PubMed ID: 20347903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
